Actavis acquired Allergan, Inc. on November 17, 2014 for $66 billion.
Allergan, Inc., is an American multinational pharmaceutical company that focuses on developing and marketing medical devices, pharmaceuticals, and over-the-counter consumer products.
It is based in Irvine, California.
The company was founded in 1950 by Gavin S. Herbert – a pharmacist who created the first antihistamine eye drop in the US.
Allergan now has a team of 10,500 employees and a presence in more than 100 countries. It operates manufacturing plants in Waco, Texas; San Jose, Costa Rica; Westport, Ireland; and Bridgewater, New Jersey.
Its leading products include: Botox® (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urinary incontinence, Restasis® (cyclosporine ophthalmic emulsion) for chronic dry eye due to inflammation, Lumigan® (bimatoprost ophthalmic solution), Botox® Cosmetic (onabotulinumtoxinA) aesthetic medical treatment, and Juvéderm® dermal fillers.
In 2014, Valeant Pharmaceuticals International Inc. teamed up with Pershing Square Capital Management to make a hostile bid for the Botox maker.
Overview
- Chairman and CEO: David E.I. Pyott
- President: Douglas S. Ingram
- Industry: Pharmaceutical
- Type: Public company
- Formed: 1948
- Revenue: $7.237 billion USD (2014)
- Net earnings: $1,528.8 million USD (2014)
- Earnings per share: $5.12 USD (2014)
- Company head office: 2525 Dupont Drive, Irvine, CA 92612-1599, USA
- Employees: 10,500 (2014)
- Website: http://www.allergan.com/
- Investor relations number: (714) 246-4636
- Investor relations email: [email protected]
Allergan, Inc., Financial Results, Years Ended December 31
| Operating data (in $ millions) | 2014 | 2013 |
| Product net sales | $7,126.1 | $6,197.5 |
| Total revenues | $7,237.9 | $6,300.4 |
| Cost of sales | $842.4 | $795.8 |
| Selling, general and administrative costs | $2,837.2 | $2,519.4 |
| Research and development | $1,191.6 | $1,042.3 |
| Operating income | $2,009.3 | $1,809.3 |
| Earnings from continuing operations | $1,532.6 | $1,272.5 |
| Net earnings | $1,528.8 | $988.7 |
| Net earnings attributable to Allergan, Inc. | $1,524.2 | $985.1 |
| Balance sheet data (in $ millions) | ||
| Total assets | $12,415.7 | $10,574.3 |
| Long-term debt | $2,085.3 | $2,098.3 |
| Total stockholders’ equity | $7,753.0 | $6,463.2 |
| Common share data (in $) | ||
| Basic earnings per share | $5.12 | $3.32 |
| Diluted earnings per share | $5.01 | $3.26 |
| Cash flow data (in $ millions) | ||
| Net cash provided by operating activities | $1,927.8 | $1,695.4 |
| Net cash used for investing activities | $182.7 | $(1,375.3) |
| Net cash provided by (used for) financing activities | $(204.0) | $28.2 |
| Cash and cash equivalents at beginning of year | $3,046.1 | $2,701.8 |
| Cash and cash equivalents at end of year | $4,911.4 | $3,046.1 |
Source: “Allergan, Inc. Form 10-K 2014”